StromaForte
AssetCell therapy
Allogeneic bone marrow-derived mesenchymal stromal cells for the prevention of cardiovascular events
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Inflammation
- Indications
- 5
- Trials
- 5
- Developers
- 2
Indications
5Aging frailty
Phase 1COMPLETEDNCT06063590clinicaltrials.gov7 Oct 2026
Cardiovascular disease
Phase 1RECRUITINGNCT06087848clinicaltrials.gov7 Oct 2026
Frailty
Phase 1NOT_YET_RECRUITINGNCT06070532clinicaltrials.gov7 Oct 2026
2 more
- Targets and what it contains2
- Owner and partners2
- Trials5
- Evidence for its targets2
- Competitors9
- Aging relevance3
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 5 sources